MEK1 and MEK2 — Drug Target

All drugs that target MEK1 and MEK2 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

MEK inhibitor

Phase 3 pipeline (1)

• Trametinib tablet · West China Hospital · MEK inhibitor · Oncology
  Trametinib is a MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes, which are involved in the MAPK/ERK signaling pathway.

Phase 1 pipeline (4)

• AZD6244 Dosing Period 1 · AstraZeneca · MEK inhibitor · Oncology
  MEK inhibitor
• AZD6244 Dosing Period 3 · AstraZeneca · MEK inhibitor · Oncology
  MEK inhibitor
• ARRY-142886, MEK inhibitor; oral · Array Biopharma, now a wholly owned subsidiary of Pfizer · MEK inhibitor · Oncology
  MEK inhibitor
• AZD6244 Dosing Period 2 · AstraZeneca · MEK inhibitor · Oncology
  MEK inhibitor